Thu Sep 19 06:24:47 UTC 2024: ## Rocket Pharmaceuticals Stock Reaffirmed as “Buy” by Needham & Company
**New York, NY – September 19, 2024** – Rocket Pharmaceuticals (NASDAQ:RCKT) received a boost on Tuesday as Needham & Company LLC reaffirmed its “buy” rating on the biotechnology company’s stock. The firm also set a price target of $52.00, representing a potential upside of 149.52% from the stock’s closing price.
This positive outlook is shared by several other analysts. Chardan Capital, JPMorgan Chase & Co., William Blair, and Cantor Fitzgerald have all issued “buy” or “overweight” ratings on Rocket Pharmaceuticals. Canaccord Genuity Group, however, reduced its price target from $49.00 to $40.00 while maintaining a “buy” rating.
Overall, MarketBeat reports an average rating of “Moderate Buy” for Rocket Pharmaceuticals, with an average price target of $52.29.
The company recently reported its quarterly earnings results, missing analysts’ estimates for earnings per share but showcasing potential for future growth.
Institutional investors continue to show strong interest in Rocket Pharmaceuticals, with several increasing their stakes in the company. This includes Janus Henderson Group PLC, Vanguard Group Inc., Franklin Resources Inc., Price T Rowe Associates Inc. MD, and First Turn Management LLC.
Rocket Pharmaceuticals is focused on developing gene therapies for rare and devastating diseases, with three clinical-stage programs currently in development.
First Piper 